KorteM.R., HabibS.M., LingsmaH., Weimar, BetjesM.G.H.Posttransplantation encapsulating peritoneal sclerosis contributes significantly to mortality after kidney transplatation.Am J Transplant2011; 11: 599.
3.
TempleS., ZaltzmanJ., PerlJ.Development of encapsulating peritoneal sclerosis in a renal transplant recipient on sirolimus immunotherapy.Perit Dial Int2010; 30: 475.
4.
AlparlslanE., NizameddinK.Everolimus-induced lymphedema in a renal transplant recipient: a case report.Experimental Clin Transplant2012; 10: 296.
5.
HuberS., BrunsC.J., SchmidG., HermannP.C., ConradC., NiessH.Inhibition of the mammalian target of rapamycin impedes lymphoangiogensis.Kidney Int2007; 71: 771.
6.
DumanS., BozkurtD., SipahiS., SezakM., OzkanS., ErtilavM.Effects of everolimus as an antiproliferative agent on regression of encapsulating peritoneal sclerosis in a rat model.Adv Perit Dial2008; 24: 104.
7.
WrightB., SummersA., FennerJ., GillottR., HutchinsonC.E., SpencerP.A.Initial observations using a novel “cine” magnetic resonance imaging technique to detect changes in abdominal motion caused by encapsulating peritoneal sclerosis.Perit Dial Int2011; 31: 287.
